In Brief: Wyeth/Elan Naprelan
Executive Summary
Wyeth/Elan Naprelan: Elan Pharma neurological sales force of 60 reps will begin promoting Naprelan (naproxen controlled-release) to neurologists, and physical medicine and rehabilitation specialists. Wyeth-Ayerst has been marketing the once-daily arthritis pain medication, which uses Elan's Intestinal Protective Drug Absorption System, to general practitioners, family practice and internal medicine physicians since April 1996. Naprelan is the first product to be marketed by the Elan Pharma neurological sales force. The group plans to promote Elan subsidiary Athena's anti-epileptic Diastat (diazepam gel), which the firm expects to be approved later this year...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth